3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Phase 1
1
Status
Completed
3
Recruiting
2
Terminated
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Gynecologic
2
Breast
2
Head & Neck
1
Conditions
Breast Neoplasms
37
Neoplasm Metastasis
6
Neoplasms
3
Ovarian Neoplasms
2
Hereditary Sensory and Autonomic Neuropathies
2
Endometrial Neoplasms
2
Carcinoma, Ovarian Epithelial
2
Breast Neoplasms, Male
2
Breast Diseases
2
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumors
1
Neoplasms by Site
1
Medulloblastoma
1
Lung Neoplasms
1
Locoregional Recurrence
1
Locally Advanced (Inoperable) or Metastatic Breast Cancer
1
Head and Neck Neoplasms
1
HR+/HER2- Breast Cancer
1
HER2 Negative Breast Cancer
1
Glioma
1
Glioblastoma
1
Fallopian Tube Neoplasms
1
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
1
ER+ HER2- Advanced Breast Cancer
1
Digestive System Neoplasms
1
Diffuse Intrinsic Pontine Glioma
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Bevacizumab
40
Paclitaxel
35
Carboplatin
28
pembrolizumab
21
Cyclophosphamide
15
Specimen Handling
14
Cisplatin
13
olaparib
11
Blood Specimen Collection
11
niraparib
10
fludarabine
10
Magnetic Resonance Spectroscopy
9
Drug Therapy
9
liposomal doxorubicin
8
Topotecan
8
Taxes
8
Gemcitabine
8
Biopsy
8
Fulvestrant
7
Doxorubicin
6
cemiplimab
5
abemaciclib
5
Surveys and Questionnaires
5
Standard of Care
5
Injections
5
Fluorouracil
5
Cytoreduction Surgical Procedures
5
trastuzumab deruxtecan
4
mirvetuximab soravtansine
4
aldesleukin
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Recruiting
×
Ovarian Neoplasms
×
ribociclib
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled
NCT04315233
2025-04-22
CHARGE
University of Utah
Phase 1
Recruiting
34 enrolled